

INSTITUTIONAL REVIEW BOARD APPLICATION PACKET
(Incomplete applications will not be accepted)

Includes:

Human Subjects Review Application

Adverse Event Report Form

Annual Renewal/Completion Report Form






Listing of deadline dates for the submission of research applications

Cleveland Clinic Foundation
Institutional Review Board, Wb2
Extension: 42924 Fax: 54094

Assigned:
IRB#: _____ Review Month:

- 1 Principal Investigator (PI) Hiroshi Kobayashi
Department Urology Mail Code A.19.1 Phone 4-4402 Fax 445-6049
- 2 Title of Project: Changes in frequency of sperm chromosomal anomalies after chemotherapy for testicular cancer and Hodgkin's disease: a longitudinal study.
- 3 Project Period: From 02/1999 To 01/2000
4. Funding: Internal: _____ (Internal Source): X No Funding:
External: _____ (External Source):
(If this study involves funding contact the RPC Office ext. 42295, NC11).
- 4a If you are obtaining funding from a commercial sponsor, has the \$500.00 IRB review and monitoring fee been asked for? _____ Yes Provide cost center, if available
_____ X No Please explain why

Collaborating Investigators

Name/Signature:	Mail Code/Dept.	Phone
<u>Rakesh K. Sharma, Ph.D.</u> 	<u>A-19.1 Urology/Andrology</u>	<u>44402</u>
<u>Thomas E. Olencki, D.O.</u> 	<u>T-40 Hematology/Oncology</u>	<u>47774</u>
<u>David Peereboom, M.D.</u> 	<u>T-40 Hematology/Oncology</u>	<u>56068</u>
<u>Anthony J Thomas, Jr M.D.</u> 	<u>Urology</u>	<u>46340</u>
<u>Ashok Agarwal, Ph.D.</u> 	<u>A-19.1 Urology/Andrology</u>	<u>49485</u>

6 Signatures/Assurances:

This research project is consistent with FDA regulations and IRB requirements. The Principal Investigator accepts scientific responsibility and agrees to notify the IRB of any adverse events involving human subjects, and provide annual and final reports of progress.

Hiroshi Kobayashi
Principal Investigator/Date

Andrew Ravel
Department Chairman/Date